Total Revenue is expected to increase by a high single-digit percentage; The Core Tax rate is expected to be between 18-22%. Guidance for FY25 at CER.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
- China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz
- U.K. defends negotiations with AstraZeneca, BBC News reports
- Is AZN a Buy, Before Earnings?
- AstraZeneca’s Imfinzi recommended for approval in EU by CHMP